These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8797687)

  • 1. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report.
    Gringeri A; Santagostino E; Cusini M; Muça-Perja M; Marinoni A; Mannucci PM; Burny A; Criscuolo M; Lu W; Andrieru JM; Mbika JP; Lachgar A; Fall LS; Chams V; Feldman M; Hermans P; Zagury JF; Bizzini B; Musicco M; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Sep; 13(1):55-67. PubMed ID: 8797687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).
    Gringeri A; Musicco M; Hermans P; Bentwich Z; Cusini M; Bergamasco A; Santagostino E; Burny A; Bizzini B; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):358-70. PubMed ID: 10096580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
    Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological effect of active anti-IFN alpha immunization in HIV-infected patients.
    Fall LS; M'Bika JP; Le Coq H; Fouchard M; Astgen A; Bizzini B; Gringeri A; Santagostino E; Burny A; Zagury D
    Biomed Pharmacother; 1995; 49(9):422-8. PubMed ID: 8746078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression.
    Gringeri A; Santagostino E; Mannucci PM; Siracusano L; Marinoni A; Criscuolo M; Carcagno M; Fall LS; M'Bika JP; Bizzini B
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):381-7. PubMed ID: 7580831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
    Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
    AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.
    Palma P; Romiti ML; Li Pira G; Montesano C; Mora N; Aquilani A; Santilli V; Tchidjou HK; Ivaldi F; Giovannelli L; Pontrelli G; Borra G; Blomberg P; Gudmundsdotter L; Bråve A; Montano M; Bernardi S; Manca F; Wahren B; Rossi P
    Vaccine; 2011 Sep; 29(39):6810-6. PubMed ID: 21216310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.
    Lane HC; Davey V; Kovacs JA; Feinberg J; Metcalf JA; Herpin B; Walker R; Deyton L; Davey RT; Falloon J
    Ann Intern Med; 1990 Jun; 112(11):805-11. PubMed ID: 1971503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
    Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of recombinant interferon-alpha in human immunodeficiency virus (HIV)-infected individuals.
    Rivero J; Limonta M; Aguilera A; Fraga M; López Saura P
    Biotherapy; 1994; 8(1):23-31. PubMed ID: 7547078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.
    Zagury D; Lecoq H; Gervi I; Le Buanec H; Zagury JF; Bizzini B; Burny A; Hermans P; Perja M; Santagostino E; Gringeri A
    Biomed Pharmacother; 1999 Mar; 53(2):90-2. PubMed ID: 10337463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of interferon alpha therapy for HIV type 1 infection.
    Haas DW; Lavelle J; Nadler JP; Greenberg SB; Frame P; Mustafa N; St Clair M; McKinnis R; Dix L; Elkins M; Rooney J
    AIDS Res Hum Retroviruses; 2000 Feb; 16(3):183-90. PubMed ID: 10710206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients.
    Brockmeyer NH; Poffhoff A; Bader A; Hochdorfer B; Schlottmann R; Rasokat H; Altmeyer P; Kreuter A
    Eur J Med Res; 2006 Jan; 11(1):27-32. PubMed ID: 16504957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease progression markers during asymptomatic phase of HIV-1 infected children with unimpaired CD4+ cell values: evaluation of repeat CD4+ cell evaluation vs. other immunological parameters.
    Chattopadhya D; Baveja UK; Bose M; Kumar A
    J Trop Pediatr; 2002 Dec; 48(6):340-7. PubMed ID: 12521275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.